Cambridge, Massachusetts-based Acceleron Pharma announced that the company’s Phase II clinical trial of ACE-083 in patients with Charcot-Marie-Tooth disease (CMT) failed to show functional improvement.
Israel’s Nobio Ltd. received approval from the U.S. Food and Drug Administration to market an anti-bacterial composite designed to remain in the teeth for decades.
Environmental factors appear to play a bigger role than genetics in shaping children’s risk for cavities, a study of Australian twins suggests.
Todd Campbell, writing for The Motley Fool, notes four biopharma stocks that topped out in the S&P 500 in 2017.
The most recent federal data reveals that over half of U.S. children consumed so much fluoride it permanently discolored their teeth, while cavity rates have increased, reports the New York State Coalition Opposed to Fluoridation Inc. (NYSCOF).
Danaher Corp. said it would buy medical diagnostics company Cepheid in a deal valued at $4 billion that will strengthen its presence in molecular diagnostics.
A filling is one of the most common procedures carried out by dentists. But just the thought of anesthetic injections followed by the sound of the drill is enough to send shivers down the spine of many people. But a new technology developed by British scientists could dramatically reduce the need for unpleasant dental drilling. […]